Cell and gene therapy (CGT) is transforming medicine, with a global market projected to exceed $80–100B by 2030 and more than 2,000 active clinical trials worldwide. Yet manufacturing complexity, CMC constraints, and cost pressures continue to limit scalability and patient access. In this presentation, we explore practical strategies to improve manufacturing reliability, reduce risk, and enhance production efficiency across the CGT lifecycle. Drawing on real-world case studies in complex CAR-T and viral vector programs, we will discuss construct “health checks,” process optimization approaches and the importance of adaptable yet controlled manufacturing platforms. We will also highlight how operational flexibility and lean principles can significantly reduce the cost of goods while maintaining high success rates. Ultimately, we suggest approaches to change CMC challenges from a liability to competitive advantage for developers.